4.5 Review

Cancer vaccines: the next immunotherapy frontier

期刊

NATURE CANCER
卷 3, 期 8, 页码 911-926

出版社

NATURE PORTFOLIO
DOI: 10.1038/s43018-022-00418-6

关键词

-

类别

资金

  1. Swedish Research Council [2017-00565]
  2. Swedish Society for Medical Research (SSMF) [P16-0026]
  3. Swedish Research Council [2017-00565] Funding Source: Swedish Research Council

向作者/读者索取更多资源

The article discusses the current status and potential of cancer vaccines, emphasizing the need for accurate immune monitoring of early trials to advance the most promising vaccines. It also classifies cancer vaccines based on the included antigens and their colocalization with antigen-presenting cells, highlighting the challenges and opportunities in advancing these vaccines to the clinic.
Brody and colleagues discuss the current status and potential of cancer vaccines, highlighting challenges and opportunities to advance promising candidates to the clinic. After several decades, therapeutic cancer vaccines now show signs of efficacy and potential to help patients resistant to other standard-of-care immunotherapies, but they have yet to realize their full potential and expand the oncologic armamentarium. Here, we classify cancer vaccines by what is known of the included antigens, which tumors express those antigens and where the antigens colocalize with antigen-presenting cells, thus delineating predefined vaccines (shared or personalized) and anonymous vaccines (ex vivo or in situ). To expedite clinical development, we highlight the need for accurate immune monitoring of early trials to acknowledge failures and advance the most promising vaccines.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据